There Are Plenty of Eli Lilly Bulls: Here’s What They Aren’t Telling You
Eli Lilly (LLY) reported Q2 revenue of $22.97B, up 47.67% YoY, and raised full-year guidance to $85B-$87B. Despite a 27% EPS beat, shares fell 14% post-earnings due to a 13% drop in net prices. LLY trades at 37x trailing earnings but has lagged the S&P 500 this year. Management warned of further price declines.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise expectations, but the price decline reflects market concerns over net‑price erosion and pricing pressure.
Market read
Earnings surprise with significant guidance lift for a mega‑cap pharma; price reaction creates short‑term trading opportunity.
What to watch
Net‑price declines and upcoming weight‑loss drug submissions could drive future growth beyond the earnings beat.
Background
Eli Lilly reported Q2 results with revenue up 47.7% YoY, EPS beat by 27%, and raised full‑year revenue guidance, yet the stock fell 14% on earnings day.
Ticker impact
Q2 earnings beat estimates with revenue up 47.7% YoY, EPS $8.38, and full‑year revenue guidance raised to $85‑87 B; stock fell 14% on the day.
Potential further downside as investors digest price‑pressure and net‑price decline concerns.
Large‑cap pharma with material earnings numbers and a double‑digit price move on the same day; traders can act on the disconnect between fundamentals and price.
Market effects
Highlights pricing pressure in large‑cap pharma; may affect peers with similar net‑price trends.
U.S. pharma sector sees modest pullback amid earnings disappointment.
Eli Lilly's guidance influences global biotech sentiment given its market‑cap size.
Counterpoint
Despite the 14% drop, the raised guidance and strong pipeline could support a rebound, presenting a buying opportunity.
Key entities
- CompanyEli Lilly
Large‑cap pharmaceutical company reporting Q2 earnings.
